TABLE OF CONTENTS
1 INTRODUCTION 42
1.1 OBJECTIVES OF THE STUDY 42
1.2 MARKET DEFINITION 42
1.3 OVERVIEW OF THE GLOBAL CONTRACT MANUFACTURING MARKET 42
1.4 CURRENCY AND PRICING 44
1.5 LIMITATIONS 44
1.6 MARKETS COVERED 44
2 MARKET SEGMENTATION 47
2.1 MARKETS COVERED 47
2.2 GEOGRAPHICAL SCOPE 48
2.3 YEARS CONSIDERED FOR THE STUDY 49
2.4 DBMR TRIPOD DATA VALIDATION MODEL 50
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 53
2.6 MULTIVARIATE MODELLING 54
2.7 PRODUCT SEGMENT LIFELINE CURVE 54
2.8 MARKET END USER COVERAGE GRID 55
2.9 DBMR MARKET POSITION GRID 56
2.10 VENDOR SHARE ANALYSIS 57
2.11 SECONDARY SOURCES 58
2.12 ASSUMPTIONS 58
3 EXECUTIVE SUMMARY 59
4 PREMIUM INSIGHTS 61
4.1 PESTEL ANALYSIS 64
4.2 PORTER'S FIVE FORCES 65
4.3 STRATEGIC INITIATIVES: 66
5 REGULATORY FRAMEWORK 67
5.1 REGULATORY SCENARIO BY FDA 67
5.2 REGULATORY SCENARIO IN AUSTRALIA 68
5.3 REGULATORY SCENARIO IN EUROPE FOR MEDICINES 69
6 MARKET OVERVIEW 70
6.1 DRIVERS 72
6.1.1 COST-EFFECTIVENESS FOR THE MANUFACTURING COMPANIES 72
6.1.2 RISE OF TECHNOLOGICAL ADVANCEMENTS IN CONTRACT MANUFACTURING 72
6.1.3 GLOBAL PRESENCE AND CONNECTED NETWORK 73
6.2 RESTRAINTS 73
6.2.1 STRINGENT REGULATIONS AMONG VARIOUS JURISDICTIONS 73
6.2.2 RISK OF CONFIDENTIAL INFORMATION 74
6.3 OPPORTUNITIES 74
6.3.1 PATENT EXPIRY AND INCREASING DEMAND FOR GENERIC DRUGS 74
6.3.2 GROWING EXPENSES ON THE DEVELOPMENT OF HEALTHCARE INFRASTRUCTURE 75
6.3.3 INCREASE IN NUMBER OF STRATEGIC INITIATIVES BY KEY MARKET PLAYERS 75
6.4 CHALLENGES 76
6.4.1 INTELLECTUAL PROPERTY RISKS 76
6.4.2 INCREASE IN NUMBER OF PHARMACEUTICAL COMPANIES TO SET UP THEIR MANUFACTURING SITES 76
7 GLOBAL CONTRACT MANUFACTURING MARKET, BY PRODUCT 77
7.1 OVERVIEW 78
7.2 PHARMACEUTICAL PRODUCTS MANUFACTURING 81
7.2.1 TYPES OF PRODUCTS 82
7.2.1.1 TABLETS 82
7.2.1.2 CAPSULES 82
7.2.1.3 BIOLOGICS 83
7.2.1.4 SMALL MOLECULE 83
7.2.1.5 CELL & GENES MANUFACTURING 83
7.2.1.6 NUTRACEUTICALS 83
7.2.1.7 OTHERS 83
7.2.2 TYPE OF SERVICES 83
7.2.2.1 DRUG DEVELOPMENT SERVICES 84
7.2.2.2 TABLET MANUFACTURING SERVICES 84
7.2.2.3 BIOLOGICS API MANUFACTURING 84
7.2.2.4 BIOLOGICS FDF MANUFACTURING SERVICES 84
7.2.2.5 OTHERS 84
7.2.3 BY DOSAGE FORM 84
7.2.3.1 SOLID FORMULATIONS 85
7.2.3.2 LIQUID FORMULATIONS 85
7.2.3.2.1 INJECTABLE 85
7.2.3.2.2 SYRUPS 85
7.2.3.3 SEMI-SOLID FORMULATIONS 85
7.2.3.4 TOPICAL DRUG FORMULATIONS 85
7.2.3.5 OTHERS 85
7.3 MEDICAL DEVICE MANUFACTURING 86
7.3.1 TYPE OF DEVICES 87
7.3.1.1 SYRINGES AND NEEDLES 88
7.3.1.2 INFUSION DEVICES & ADMINISTRATION SETS 88
7.3.1.3 MEDICAL ACCESSORIES, COMPONENTS & CONSUMABLES 88
7.3.1.4 DISPOSABLES 88
7.3.1.5 IVD DEVICES 89
7.3.1.6 CARDIOVASCULAR DEVICES 89
7.3.1.7 DIABETES CARE DEVICES 89
7.3.1.8 GENERAL SURGERY DEVICES 89
7.3.1.9 ORTHOPEDIC DEVICES 89
7.3.1.10 RESPIRATORY DEVICES 89
7.3.1.11 OPHTHALMIC DEVICES 89
7.3.1.12 DENTAL DEVICES 89
7.3.1.13 GYNECOLOGY/UROLOGY DEVICES 89
7.3.1.14 LABORATORY EQUIPMENT 89
7.3.2 TYPE OF SERVICES 90
7.3.2.1 MEDICAL DEVICE DESIGN AND DEVELOPMENT 90
7.3.2.2 DEVICE ASSEMBLY 90
7.3.2.3 REGULATORY ASSISTANCE 90
7.3.2.4 PACKAGING & LABELLING 90
7.3.2.5 STERILIZATION SERVICES 91
7.3.2.6 TRAINING AND VALIDATION 91
7.3.2.7 QUALITY ASSURANCE 91
7.3.2.8 OTHERS 91
7.3.3 BY DEVICE CLASS 91
7.3.3.1 CLASS I MEDICAL DEVICES 92
7.3.3.2 CLASS IIA MEDICAL DEVICES 92
7.3.3.3 CLASS IIB MEDICAL DEVICES 92
7.3.3.4 CLASS III MEDICAL DEVICES 92
8 GLOBAL CONTRACT MANUFACTURING MARKET, BY END USER 93
8.1 OVERVIEW 94
8.2 PHARMACEUTICAL COMPANIES 97
8.3 BIOTECHNOLOGY COMPANIES 97
8.4 BIOPHARMA COMPANIES 98
8.5 MEDICAL DEVICES COMPANIES 99
8.6 ORIGINAL EQUIPMENT MANUFACTURER 99
8.7 RESEARCH INSTITUTES 100
9 GLOBAL CONTRACT MANUFACTURING MARKET, BY DISTRIBUTION CHANNEL 101
9.1 OVERVIEW 102
9.2 RETAIL SALES 105
9.3 DIRECT TENDER 106
9.4 OTHERS 107
10 GLOBAL CONTRACT MANUFACTURING MARKET, BY REGION 108
10.1 OVERVIEW 109
10.2 NORTH AMERICA 114
10.2.1 U.S. 125
10.2.2 CANADA 132
10.2.3 MEXICO 139
10.3 EUROPE 146
10.3.1 GERMANY 159
10.3.2 FRANCE 167
10.3.3 U.K. 175
10.3.4 ITALY 183
10.3.5 SPAIN 191
10.3.6 RUSSIA 199
10.3.7 TURKEY 207
10.3.8 BELGIUM 215
10.3.9 NETHERLANDS 223
10.3.10 SWITZERLAND 231
10.3.11 REST OF EUROPE 239
10.4 ASIA PACIFIC 240
10.4.1 JAPAN 253
10.4.2 CHINA 261
10.4.3 SOUTH KOREA 269
10.4.4 INDIA 276
10.4.5 AUSTRALIA 284
10.4.6 SINGAPORE 292
10.4.7 THAILAND 300
10.4.8 MALAYSIA 308
10.4.9 INDONESIA 316
10.4.10 PHILIPPINES 324
10.4.11 REST OF ASIA-PACIFIC 332
10.5 SOUTH AMERICA 333
10.5.1 BRAZIL 346
10.5.2 ARGENTINA 354
10.5.3 REST OF SOUTH AMERICA 362
10.6 MIDDLE EAST AND AFRICA 363
10.6.1 SOUTH AFRICA 376
10.6.2 SAUDI ARABIA 384
10.6.3 U.A.E. 392
10.6.4 EGYPT 400
10.6.5 ISRAEL 408
10.6.6 REST OF MIDDLE EAST AND AFRICA 416
11 GLOBAL CONTRACT MANUFACTURING MARKET: COMPANY LANDSCAPE 417
11.1 COMPANY SHARE ANALYSIS: GLOBAL 417
11.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 418
11.3 COMPANY SHARE ANALYSIS: EUROPE 419
11.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 420
12 SWOT ANALYSIS 421
13 COMPANY PROFILE 422
13.1 AENOVA GROUP 422
13.1.1 COMPANY SNAPSHOT 422
13.1.2 COMPANY SHARE ANALYSIS 422
13.1.3 PRODUCT PORTFOLIO 423
13.1.4 RECENT DEVELOPMENTS 423
13.2 THERMO FISHER SCIENTIFIC INC. 424
13.2.1 COMPANY SNAPSHOT 424
13.2.2 REVENUE ANALYSIS 425
13.2.3 COMPANY SHARE ANALYSIS 425
13.2.4 PRODUCT PORTFOLIO 426
13.2.5 RECENT DEVELOPMENTS 426
13.3 EVONIK INDUSTRIES AG 427
13.3.1 COMPANY SNAPSHOT 427
13.3.2 REVENUE ANALYSIS 427
13.3.3 COMPANY SHARE ANALYSIS 428
13.3.4 PRODUCT PORTFOLIO 428
13.3.5 RECENT DEVELOPMENTS 428
13.4 LONZA 429
13.4.1 COMPANY SNAPSHOT 429
13.4.2 REVENUE ANALYSIS 429
13.4.3 COMPANY SHARE ANALYSIS 430
13.4.4 PRODUCT PORTFOLIO 430
13.4.5 RECENT DEVELOPMENTS 431
13.5 BOEHRINGER INGELHEIM INTERNATIONAL GMBH. 432
13.5.1 COMPANY SNAPSHOT 432
13.5.2 REVENUE ANALYSIS 432
13.5.3 COMPANY SHARE ANALYSIS 433
13.5.4 PRODUCT PORTFOLIO 433
13.5.5 RECENT DEVELOPMENTS 433
13.6 ABBVIE INC. 434
13.6.1 COMPANY SNAPSHOT 434
13.6.2 REVENUE ANALYSIS 434
13.6.3 PRODUCT PORTFOLIO 435
13.6.4 RECENT DEVELOPMENT 435
13.7 ALMAC GROUP 436
13.7.1 COMPANY SNAPSHOT 436
13.7.2 PRODUCT PORTFOLIO 436
13.7.3 RECENT DEVELOPMENTS 436
13.8 AVID BIOSERVICES, INC. 437
13.8.1 COMPANY SNAPSHOT 437
13.8.2 REVENUE ANALYSIS 437
13.8.3 PRODUCT PORTFOLIO 438
13.8.4 RECENT DEVELOPMENT 438
13.9 BAXTER 439
13.9.1 COMPANY SNAPSHOT 439
13.9.2 REVENUE ANALYSIS 439
13.9.3 PRODUCT PORTFOLIO 440
13.9.4 RECENT DEVELOPMENTS 441
13.10 CATALENT, INC 442
13.10.1 COMPANY SNAPSHOT 442
13.10.2 REVENUE ANALYSIS 442
13.10.3 PRODUCT PORTFOLIO 443
13.10.4 RECENT DEVELOPMENT 443
13.11 FAMAR HEALTH CARE SERVICES 444
13.11.1 COMPANY SNAPSHOT 444
13.11.2 PRODUCT PORTFOLIO 444
13.11.3 RECENT DEVELOPMENTS 444
13.12 JUBILANT PHARMA LIMITED 445
13.12.1 COMPANY SNAPSHOT 445
13.12.2 REVENUE ANALYSIS 445
13.12.3 PRODUCT PORTFOLIO 446
13.12.4 RECENT DEVELOPMENT 446
13.13 KIMBALL INTERNATIONAL 447
13.13.1 COMPANY SNAPSHOT 447
13.13.2 REVENUE ANALYSIS 447
13.13.3 PRODUCT PORTFOLIO 448
13.13.4 RECENT DEVELOPMENT 448
13.14 MERCK KGAA 449
13.14.1 COMPANY SNAPSHOT 449
13.14.2 REVENUE ANALYSIS 449
13.14.3 PRODUCT PORTFOLIO 450
13.14.4 RECENT DEVELOPMENTS 450
13.15 NIPR0 451
13.15.1 COMPANY SNAPSHOT 451
13.15.2 REVENUE ANALYSIS 451
13.15.3 PRODUCT PORTFOLIO 452
13.15.4 RECENT DEVELOPMENT 452
13.16 PFIZER INC 453
13.16.1 COMPANY SNAPSHOT 453
13.16.2 REVENUE ANALYSIS 453
13.16.3 PRODUCT PORTFOLIO 454
13.16.4 RECENT DEVELOPMENT 454
13.17 RECIPHARM AB. 455
13.17.1 COMPANY SNAPSHOT 455
13.17.2 REVENUE ANALYSIS 455
13.17.3 PRODUCT PORTFOLIO 456
13.17.4 RECENT DEVELOPMENT 456
13.18 SIEGFRIED HOLDING AG 457
13.18.1 COMPANY SNAPSHOT 457
13.18.2 REVENUE ANALYSIS 457
13.18.3 PRODUCT PORTFOLIO 458
13.18.4 RECENT DEVELOPMENTS 458

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.